Tubulis GmbH


Tubulis - reimagining ADCs. A biotech start-up with superior next generation ADC technologies and a pipeline of pre-clinical ADC for liquid as well as solid cancers.

About us

Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight.

Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication.

Tubulis will build new conjugates to fill its pipeline and will collaborate with partners to usher in a new ADC era and deliver better outcomes for patients.

Tubulis GmbH
Butenandtstr. 1 BioSysM
81375 Munich

Phone: +49 1723 505125
Internet: www.tubulis.com

Products and Services

  • Our pipeline contains four ADC assetts

  • Our lead candiadate TUB-010 for the treatment of Hodgkin and non-Hodgkin Lymphoma will enter clinical development in 2022

  • With TUB-020 AML and TUB-030 and TUB-040 are in pre-clinical development for treatment of multiple solid tumors

Click here if you notice an image that violates copyright or privacy rights.

Get in contact

We only use functionally necessary cookies and the web analysis tool Matomo in order to optimally design and continuously improve our website for you. By continuing to use our website, you agree to this. Further information and an objection possibility can be found here: Data protection